Phase 2 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with Pulmonary Arterial Hypertension (PAH), specifically classified as Group 1 pulmonary hypertension under international medical guidelines
- People whose PAH causes slight to moderate limitations on their daily physical activities (known as WHO Functional Class II or III)
- People who are already taking standard medical treatments for PAH at a stable dose, as determined by the trial doctor
- People whose heart-lung pressure measurements (taken via a procedure called a right heart catheterisation) show resistance in the lung blood vessels at or above a certain level during the screening period (confirm with trial site for exact values)
- People who can walk between 150 and 550 metres in a 6-minute walking test, confirmed on two separate occasions during the screening period
Who may not be able to join:
- People whose pulmonary hypertension is caused by left heart disease, lung disease, low oxygen levels, blockages in the pulmonary arteries, or other unclear or mixed causes
- People whose lung blood pressure measurements during screening show a specific pressure reading above a certain threshold (confirm with trial site for exact values)
- People with a history of significant left-sided heart disease or other serious heart conditions
- People with obstructive lung disease, based on breathing test results falling below certain levels
- People with evidence of scarring or inflammation in the lung tissue (interstitial lung disease)
- People with evidence of chronic blood clots in the lung blood vessels, or a recent acute pulmonary embolism (blood clot in the lungs)
- People who need to take blood-thinning or anti-clotting medications for an existing medical condition
- People with any history of bleeding in the brain or raised pressure within the skull
- People with a history of significant bleeding events as defined by the trial protocol
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from baseline in Pulmonary Vascular Resistance (PVR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.